Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024. In the quarter to June 2026, revenue grew 27.0%, EPS fell 99.4% and free cash flow grew 1.13%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

41.22 1.12 +2.79%
Market cap
$6.7B
P/E
102×
Fwd P/E
−108×
Dividend yield
—
F-score
7/9
Altman Z
5.33
Beneish M
−3.29
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
130.02 38.02 19.03 14.49

+8 more quarters

P/S ratio
5.25 3.76 3.12 3.26
P/FCF ratio
39.30 26.57 9.57 10.09
P/Operating CF
60.28 (35.46) 27.10 48.71
P/B ratio
4.84 3.36 2.53 2.86
EV/Sales
5.76 4.40 2.42 2.71
EV/EBITDA
43.12 28.20 12.73 10.63
EV/FCF
43.10 31.08 7.43 8.41
Current Ratio
2.30 2.27 3.55 3.67
Net Debt/EBITDA
10.63 (61.92) (21.30) (11.44)
Debt/Equity
0.83 0.86 0.00 0.00
Earnings Yield
0.77% 2.63% 5.25% 6.90%
Free Cash Flow Yield
2.54% 3.76% 10.45% 9.91%
Free Cash Flow per Share
0.82 (1.02) 1.04 0.51
Book value per Share
10.83 10.54 11.05 10.50
Free Cash Flow
137.04 (169.82) 171.14 84.36
EV/EBIT
81.86 35.83 14.09 11.52
Other line items

Show all line items

Columns are period end dates